33.00 -1.67 (-4.82%)
Pre-Market: 8:11AM EST
Previous Close | 34.90 |
Open | 35.08 |
Bid | 33.00 x 800 |
Ask | 0.00 x 900 |
Day's Range | 34.00 - 35.60 |
52 Week Range | 28.97 - 52.74 |
Volume | 33,091 |
Avg. Volume | 117,021 |
Market Cap | 1.972B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 52.00 |
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that it will issue a press release on the Company's fourth quarter and full year 2020 financial results on Thursday, March 25, 2021 at 8:00 a.m. ET. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today that the company has been certified by independent analysts as a Great Place to Work® for the third year in a row. This certification is based on validated feedback from Harmony's employees in an anonymous survey intended to determine exceptional workplace cultures.
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the Company will be added to the Russell 2000® and Russell 3000® Indexes effective after the U.S. market closes on Friday, December 18.